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Abstract
Background: Earlier epidemiological studies indicate that associations between obesity and breast cancer risk may
not only depend on menopausal status and use of exogenous hormones, but might also differ by tumor subtype.
Here, we evaluated whether obesity is differentially associated with the risk of breast tumor subtypes, as defined by
6 immunohistochemical markers (ER, PR, HER2, Ki67, Bcl-2 and p53, separately and combined), in the prospective
EPIC-Germany Study (n = 27,012).
Methods: Formalin-fixed and paraffin-embedded (FFPE) tumor tissues of 657 incident breast cancer cases were
used for histopathological analyses. Associations between BMI and breast cancer risk across subtypes were evaluated
by multivariable Cox regression models stratified by menopausal status and hormone therapy (HT) use.
Results: Among postmenopausal non-users of HT, higher BMI was significantly associated with an increased risk of less
aggressive, i.e. ER+, PR+, HER2-, Ki67low, Bcl-2+ and p53- tumors (HR per 5 kg/m
2: 1.44 [1.10, 1.90], p = 0.009), but not
with risk of more aggressive tumor subtypes. Among postmenopausal users of HT, BMI was significantly inversely
associated with less aggressive tumors (HR per 5 kg/m2: 0.68 [0.50, 0.94], p = 0.018). Finally, among pre- and
perimenopausal women, Cox regression models did not reveal significant linear associations between BMI and
risk of any tumor subtype, although analyses by BMI tertiles showed a significantly lower risk of less aggressive
tumors for women in the highest tertile (HR: 0.55 [0.33, 0.93]).
Conclusion: Overall, our results suggest that obesity is related to risk of breast tumors with lower aggressiveness,
a finding that requires replication in larger-scale analyses of pooled prospective data.
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Background
Associations between etiological factors and cancer risk
have been shown to be differential across molecular
tumor subtypes in earlier epidemiological studies [1, 2].
With respect to relationships between anthropometric
factors and breast cancer risk, there is evidence to sug-
gest that obesity, as measured by body mass index
(BMI), increases the risk of estrogen receptor positive
(ER+) rather than ER- breast tumors in postmenopausal
women [3–5]. Moreover, it has been proposed that obes-
ity is related to more slowly proliferating tumors, as
defined by low expression of the Ki67 protein in tumor
cells [5]. Thus, mechanisms to link obesity with breast
cancer, especially altered estrogen and Insulin-like
growth factor 1 (IGF-1) signaling [6], could drive overall
less aggressive tumors with a distinct molecular profile.
However, despite the notion that a better understanding
of risk factor associations with tumor subtypes is needed
to improve personalized medicine and prevention [1],
prospective data on the relationship between anthropo-
metric parameters and the risks of breast cancer by
* Correspondence: t.kuehn@dkfz.de
1Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
Im Neuenheimer Feld 280, Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nattenmüller et al. BMC Cancer  (2018) 18:616 
https://doi.org/10.1186/s12885-018-4548-6
subtypes beyond those defined by hormone receptor sta-
tus are sparse [2].
The aim of the present study was to examine the associa-
tions between obesity with breast cancer risk across more
refined tumor subtypes. For this purpose, we assessed six
well-established immunohistochemical markers (ER, PR,
HER2, Ki67, Bcl-2 and p53) in tumor samples of breast can-
cer cases from the prospective European Prospective Inves-
tigation into Cancer and Nutrition (EPIC)-Germany Study.
We hypothesized that obesity would be particularly related
to the development of less aggressive tumors (i.e. ER+, PR+,
HER2-, Ki67low, Bcl-2+ and p53- tumors).
Methods
Study population
EPIC is a multi-center prospective cohort study with
more than 500,000 participants across Europe. In
Germany, 53,088 participants (30,270 women) in the age
range between 35 and 65 years were recruited at the
study centers in the cities of Heidelberg and Potsdam
between 1994 and 1998 [7, 8]. At baseline, anthropomet-
ric measurements were carried out by trained personnel,
and data on diet, physical activity, smoking, alcohol con-
sumption, medication use, reproductive factors and
socio-economic status were obtained [7].
Incident cases of breast cancer were either
self-reported during follow-up or derived from cancer
registries. Each case was validated by a study physician
using the information given by the patient’s treating phy-
sicians and hospitals. Overall, 1095 cases of primary
breast cancer had occurred until Dec 31st 2010, the
closure date for the present analyses. After exclusion of
prevalent cases of cancer (n = 1669), individuals lost to
follow-up (n = 947), individuals with unclear breast can-
cer status (n = 23), individuals with missing covariate
information (n = 181), and incident cases without tumor
blocks (n = 438) from the EPIC-Germany cohort, the
study population for the present analyses comprised
27,012 women (Additional file 1: Figure S1).
Laboratory methods
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
material was available for a total of 657 cases (60.0%).
There were no significant statistical differences regarding
age, reproductive factors and lifestyle factors between
these cases and those for which no tumor blocks were
available, even though there were slightly more in situ
and grade I tumors in the latter group (Additional file 2:
Table S1). A board-certified senior pathologist (E.H.)
selected representative tumor areas to construct tissue
microarrays (TMA) on a hematoxylin and eosin stained
slide of each tumor block. A TMA machine (AlphaMetrix
Biotech, Roedermark, Germany) was used to extract
tandem 1 mm cylindrical core samples. IHC staining was
carried out using antibodies routinely employed for diag-
nostic purposes (Additional file 2: Table S2) and an immu-
nostaining device (DAKO, Techmate 500plus). All TMA
slides were examined by at least one pathologist (E.H.,
M.K.) with special expertise in breast cancer pathology. In
case of a discrepancy between the scores derived from the
first and second core of the same patient, the pathologists
re-examined both cores and made a final decision. When-
ever TMA analysis did not yield a conclusive result for a
marker, it was assigned a missing value (ER: 2.0%; PR:
2.7%; HER2: 1.7%; Ki67: 6.1%; Bcl-2: 4.1%; p53: 6.7%).
Tumors were categorized as ER positive/negative and PR
positive/negative using the Allred Score [9]. HER2 was
determined according to staining pattern and intensity,
and scored as negative (0 and 1+) or positive (2+ and 3+)
[10]. Ki67 proliferation activity was scored by percentage
of positive tumor nuclei (< 20%: low proliferative activity;
≥20%: high proliferative activity) [11]. Bcl-2 was scored as
negative if less than 10% of the cells were positive and
staining intensity was weak, otherwise Bcl-2 was scored as
positive [12]. Cases with more than 10% of cells stained
were rated p53 positive, the remaining cases were rated
p53 negative, as in most previous studies using this anti-
gen [13]. Categorization of subtypes was based on visual
estimation counting at least 100 tumor cells.
Statistical analyses
Relationships between BMI at recruitment and breast
cancer risk were evaluated separately among 1) women,
who were pre- or perimenopausal at baseline 2) women,
who were postmenopausal at baseline and used hormone
therapy (HT), and 3) women, who were postmenopausal
at baseline and did not use HT, as differential risk asso-
ciations with BMI across these subgroups have been
reported [14, 15]. Statistical analyses on breast cancer
risk by tumor subtype were carried out using multivari-
able Cox proportional hazards regression analyses to es-
timate hazard ratios (HR) and 95% confidence intervals
(CI) across tertiles of BMI (created based on data of the
full cohort), with age as the underlying time scale. All
models were adjusted for height (continuous), number
of full-term pregnancies (continuous), educational
level (university degree vs. no university degree),
smoking status (never, former, current), and study
center (Heidelberg, Potsdam). Analyses among pre-
and perimenopausal women were further adjusted for
current use of oral contraceptives. The inclusion of
other potential confounders (alcohol consumption,
breast feeding, age at menarche, age at first preg-
nancy) only marginally affected risk associations and
were not included in final Cox regression models.
Linear trends were estimated by entering BMI as a
continuous term into the same model rescaling HRs to
reflect a 5 kg/m2 increase. Observations were
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left-truncated and censored at end of follow-up, death,
or cancer diagnosis, whichever occurred first. In order
to assess patterns of IHC markers, unsupervised hier-
archical clustering was used to group cancer cases
according to the similarity / dissimilarity of the IHC
staining results for ER, PR, HER2, Ki67, Bcl-2, and p53,
as previously published [16, 17]. In addition to BMI, we
evaluated waist circumference and hip circumference as
anthropometric markers of obesity in relation to breast
cancer risk. Heterogeneity in associations between
anthropometric factors and breast cancer risk across
subtypes was tested for using a competing risk frame-
work, as proposed by Wang et al. [18]. As the evidence
on associations between BMI and in situ breast tumors
is not consistent [19, 20], we decided to exclude cases of
in situ tumors in sensitivity analyses. All statistical ana-
lyses were carried out using SAS, version 9.4 (SAS Insti-
tute, Cary, NC, USA). For unsupervised hierarchical
clustering and for the generation of a dendogram / heat
map to visualize clusters of tumor markers we used the
d3heatmap package in R [21].
Results
Characteristics of the study population
The analytical cohort for the present analyses comprised
27,012 women at a median baseline age of 48.4 (range:
35.2–65.2) years, and a median BMI of 24.7 (see Table 1,
and Additional file 1: Figure S1). Overall, 40.8% of the
women were postmenopausal at baseline. Among the
postmenopausal women, 46.0% reported to use HT. The
average follow-up duration was 13.0 (±3.1) years.
Median age at diagnosis among the 657 breast cancer
cases was 60.2 (range: 38.9–78.6) years.
Tumor stages and grades at diagnosis were as follows;
In situ: 7.0%, Stage I: 38.7%, Stage II: 41.0%, Stage III:
11.3%, Stage IV: 2.0%; Grade I: 12.4%, Grade II: 56.8%,
Grade III: 30.8% (Additional file 2: Table S1). Of the in-
vasive tumors, 70.5% were carcinoma of no special type
(NST), 18.3% lobular carcinoma, and 11.1% other; of the
in situ tumors, 67.4% were ductal carcinoma, 13.0% were
lobular carcinoma, and 19.6% other (Additional file 2:
Table S3). The proportions of subtypes indicating
more favorable prognosis were 84.8% for ER+, 70.7%
for PR+, 87.5% for HER2-, 83.1% for Ki67low, 66.0%
for Bcl-2+ and 80.1% for p53-. Frequencies of luminal
A (ER+ and/or PR+, HER2- and Ki67low), luminal B
(ER+ and/or PR+, HER2- and Ki67high), Her2+, and
triple negative (ER-, PR-, and HER2-) tumors were
68.6, 8.4, 9.7, and 13.3%.
The results of the unsupervised hierarchical cluster-
ing of breast cancer cases according to IHC staining
profiles are shown in Fig. 1. The three main clusters
identified by hierarchical clustering can be character-
ized as follows: Cluster 1 (42.7% of all cases) contains
tumors with a profile of individual markers indicative
of low aggressiveness (all cases are ER+, PR+, HER2-,
Ki67low, Bcl-2+ and p53-). Cluster 2 (19.0% of all cases)
contains ER- tumors and ER+ tumors that are Bcl-2
negative. Cluster 3 (38.3% of all cases) mainly contains
ER+ tumors that, unlike the ER+ tumors in cluster 1,
show at least one criterion pointing to higher aggres-
siveness (i.e. p53 positivity, Bcl-2 negativity, high Ki67
expression, or HER2 positivity).
BMI and risk of breast cancer by tumor subtype
Among postmenopausal non-users of HT, BMI was
directly associated with higher overall breast cancer risk
(HR per 5 kg/m2: 1.27 [95% CI: 1.07, 1.50], p = 0.005),
while a significant inverse association was observed
among HT users (HR: 0.80 [0.66, 0.98], p = 0.024)
(Table 2). BMI was not significantly associated with
overall breast cancer risk in pre- and perimenopausal
women (HR: 0.98 [0.85, 1.12], p = 0.72).
Analyses stratified by tumor subtypes as derived from
hierarchical clustering are shown in Table 3. Among
postmenopausal non-users of HT, each 5 kg/m2 incre-
ment of BMI was directly and significantly associated
with the risk of less aggressive cluster 1 tumors, i.e.
tumors that were ER+, PR+, HER2-, Ki67low, Bcl-2+ and
p53-, with a HR per 5 kg/m2 of 1.44 [95% CI: 1.10, 1.90],
p = 0.009). BMI was not associated with more aggressive
Table 1 Characteristics of the study population
N 27,012
Age at recruitmenta 48.4 (41.2, 57.0)
Anthropometric parametersa
BMI (kg/m2) 24.7 (22.3, 28.0)
Height (cm) 163.2 (159.0, 167.5)
Menopausal Status
Pre- and perimenopausal (%) 59.2
Postmenopausal (%) 40.8
Hormone therapy (%)b
User at baseline (%) 46.0
Non-user at baseline (%) 54.0
Number of full-term pregnanciesc 1.7 (0, 8)
Smoking Status
Never smokers (%) 55.7
Former smokers (%) 25.6
Current smokers (%) 18.7
Education Level
University Degree (%) 34.4
No University Degree (%) 65.6
aMedian values (p25, 75) are shown for continuous variables
bPostmenopausal women only
cMean value (Minimum, Maximum)
Nattenmüller et al. BMC Cancer  (2018) 18:616 Page 3 of 8
cluster 2 and cluster 3 tumors (Table 3). Among
HT-users, BMI was significantly associated with lower
risk of less aggressive cluster 1 tumors (HR per 5 kg/m2:
0.68 [0.50, 0.94], p = 0.018); again, no significant associa-
tions with the risks of more aggressive cluster 2 and
cluster 3 tumors were observed. While risk analyses per
5 kg/m2 did not reveal significant associations between
BMI and risks of any tumor subtype in pre- and peri-
menopausal women, it is of note that women in the
highest BMI tertile showed a significantly lower risk of
less aggressive cluster 1 tumors as compared to women
in the lowest BMI tertile (HRTertile3 vs. Tertile1: 0.55 [0.33,
0.93]). Sensitivity analyses excluding in situ cases yielded
similar highly similar results (Additional file 2: Table S4).
Associations between BMI and risk of luminal A tumors
were similar to those between BMI and risk of cluster 1
tumors (Additional file 2: Table S5); there were no sig-
nificant associations with luminal B and triple negative
tumors.
In analyses on breast tumor subtypes defined by indi-
vidual markers, BMI was significantly positively associ-
ated with risk of ER+, PR+, HER2-, Ki67low, Bcl-2+ and
p53- tumors among postmenopausal non-users of HT
(Additional file 2: Table S6). By contrast, no significant
associations with ER-, PR-, HER2+, Ki67high, Bcl-2- and
p53+ tumors were observed. With respect to postmeno-
pausal users of HT, Cox regression analyses showed
significant inverse associations with risks of ER+, HER2-,
Ki67low, Bcl-2+ and p53- tumors, and a non-significant
tendency for an inverse association with PR+ breast
cancer (Additional file 2: Table S7). Again, there were no
significant associations with risk of ER-, PR-, HER2+,
Fig. 1 Frequencies of combined tumor subtypes as derived from hierarchical clustering, with the top three clusters marked in the dendrogram;
light bars indicate positivity (or high proliferation activity in case of Ki67)
Table 2 Hazard ratios of overall breast cancer across tertiles of BMIa
Postmenopausal non-users of HTb Postmenopausal users of HTb Pre- and perimenopausal womenb
Cases (n) HR CI (95%) Cases (n) HR CI (95%) Cases (n) HR CI (95%)
Tertile 1 14 1 65 1 141 1
Tertile 2 43 1.87 (1.00,3.49) 92 0.97 (0.70,1.34) 85 0.76 (0.57,1.00)
Tertile 3 79 2.28 (1.23,4.16) 56 0.69 (0.47,1.00) 82 0.93 (0.70,1.24)
Per 5 kg/m2 1.27 (1.07,1.50) 0.80 (0.66,0.98) 0.98 (0.85,1.12)
p trend 0.005 0.024 0.72
Median (p25, p75) values of BMI: Tertile 1: 21.4 (20.4, 22.3), Tertile 2: 24.8 (23.9, 25.7); Tertile 3: 29.9 (28.1, 32.7)
aFrom Cox regression models adjusted for height, number of full-term pregnancies, pill use, education level, smoking status, and study center
bAt baseline (HT hormone therapy)
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Ki67high, Bcl-2- and p53+ tumors. Among pre- and peri-
menopausal women, BMI was not significantly associ-
ated with risks of any tumor subtype defined by
individual markers (Additional file 2: Table S8). The
results on BMI and risks of tumor subtypes defined by
individual markers were similar after exclusion of in situ
cases (see Additional file 2: Table S9, Table S10, and
Table S11).
The directions of associations with risk of tumor sub-
types were highly similar when using waist and hip
circumference as anthropometric indices of obesity in-
stead of BMI, while the associations between
waist-to-hip ratio and breast cancer risk were weaker
and non-significant (data not shown). Risk associations
among premenopausal women only were very similar as
the presented associations among peri- and premeno-
pausal women (data not shown). Importantly, no formal
heterogeneity of associations between anthropometric
factors and breast cancer risk across tumor subtypes, as
either derived from hierarchical clustering or defined by
individual IHC markers, was observed.
Discussion
Here, we examined associations between BMI and breast
cancer risk by tumor subtypes characterized by six
immunohistochemical markers. Among postmenopausal
women who did not use HT at the time of recruitment,
higher BMI was significantly associated with increased
risk of less aggressive tumors, as either defined by indi-
vidual markers (ER+, PR+, HER2-, Ki67low, Bcl-2+, p53-)
or a combination of these markers derived from hier-
archical cluster analysis (cluster 1). By contrast, we
observed no significant associations between BMI and
risk of more aggressive tumors, irrespective of whether
subtype classification was based on single markers or on
marker combinations (clusters 2 and 3). Among HT
users, higher BMI was linearly associated with reduced
relative risk of less aggressive (hormone receptor posi-
tive, HER-, Ki67low, Bcl-2+, or cluster 1) tumors, while
there were no significant associations with more aggres-
sive tumors. Analyses by single markers did not reveal
any significant associations among pre- and perimeno-
pausal women, whereas risk of cluster 1 tumors was
lower among women in the highest BMI tertile com-
pared to those in the lowest.
Various studies have shown associations between
obesity and an increased risk of breast cancer among
postmenopausal non-users of HT, particularly of ER+
/ PR+ breast cancer, but not ER- / PR- breast cancer
[4, 22, 23]. Our present data confirm the association
Table 3 Hazard ratios of breast cancer across tertiles of BMI by clusters of breast tumors from hierarchical clustering (see Fig. 1)a
Postmenopausal
non-users of HTb
Postmenopausal
users of HTb
Pre- and perimenopausal
womenb
Cases
(n)
HR CI (95%) Cases
(n)
HR CI (95%) Cases
(n)
HR CI (95%)
Cluster 1 Tertile 1 4 1 Tertile 1 30 1 Tertile 1 59 1
(ER+, PR+, HER2-, Ki67low, bcl-2+,
and p53-)
Tertile 2 8 1.02 (0.31,3.40) Tertile 2 32 0.74 (0.44,1.22) Tertile 2 31 0.64 (0.41,1.00)
Tertile 3 33 2.50 (0.86,7.23) Tertile 3 24 0.61 (0.35,1.06) Tertile 3 21 0.55 (0.33,0.93)
Per 5 kg/m2 1.44 (1.10,1.90) Per 5 kg/m2 0.68 (0.50,0.94) Per 5 kg/m2 0.85 (0.67,1.08)
p trend 0.009 p trend 0.018 p trend 0.19
Cluster 2 Tertile 1 5 1 Tertile 1 10 1 Tertile 1 18 1
(ER- or ER+ that are Bcl-2-) Tertile 2 6 0.77 (0.23,2.56) Tertile 2 18 1.14 (0.52,2.53) Tertile 2 9 0.59 (0.26,1.32)
Tertile 3 16 1.40 (0.49,4.04) Tertile 3 6 0.43 (0.15,1.21) Tertile 3 20 1.52 (0.77,3.00)
Per 5 kg/m2 1.15 (0.78,1.70) Per 5 kg/m2 0.83 (0.52,1.32) Per 5 kg/m2 1.22 (0.91,1.62)
p trend 0.47 p trend 0.42 p trend 0.18
Cluster 3 Tertile 1 5 1 Tertile 1 20 1 Tertile 1 48 1
(ER+ with at least one other marker
indicative of higher aggressiveness)
Tertile 2 21 2.98 (1.01,8.75) Tertile 2 33 1.20 (0.68,2.12) Tertile 2 26 0.72 (0.44,1.18)
Tertile 3 16 1.57 (0.51,4.83) Tertile 3 17 0.77 (0.39,1.51) Tertile 3 31 1.13 (0.70,1.82)
Per 5 kg/m2 1.00 (0.71,1.42) Per 5 kg/m2 0.82 (0.58,1.15) Per 5 kg/m2 0.94 (0.74,1.19)
p trend 0.99 p trend 0.24 p trend 0.60
Median (p25, p75) values of BMI: Tertile 1: 21.4 (20.4, 22.3), Tertile 2: 24.8 (23.9, 25.7); Tertile 3: 29.9 (28.1, 32.7)
No statistical heterogeneity of HRs across subtypes was observed
aFrom Cox regression models adjusted for height, number of full-term pregnancies, pill use, education level, smoking status, and study center bAt baseline (HT
hormone therapy)
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with hormone-receptor positive breast cancer and
additionally indicate that postmenopausal obesity may
be related to an overall less aggressive molecular sub-
type of breast cancer characterized by a lower prolif-
eration rate (Ki67low), Bcl-2 positivity and p53
negativity – immunohistochemical characteristics that
are each associated with better prognosis [12, 24–26].
The inverse overall association between obesity and
breast cancer risk among HT users that we observed
is in agreement with previous data from the full
EPIC-Europe cohort [27]. Our results suggest that
this inverse association might be strongest for (if not
restricted to) the less aggressive tumor subtypes,
which is in contrast, however, with earlier observa-
tions in the EPIC-Europe Study, which were suggest-
ive of an inverse association between BMI and breast
cancer risk among users of HT for ER- / PR- but not
ER+ / PR+ tumors [4]. Thus, and given the lack of
further studies on obesity and breast cancer risk by
tumor subtypes among HT users [28], the associa-
tions observed in the present study require replica-
tion. Our observation of a lower risk of less
aggressive tumors among pre- and perimenopausal
women in the highest BMI tertile is consistent with
results of a meta-analysis, in which BMI was signifi-
cantly inversely associated with the risk of ER+/PR+
tumors but not ER-/PR- tumors in premenopausal
women [22].
Biological mechanisms that may underlie the associ-
ation between obesity and breast cancer include altered
sex hormone metabolism, adipokine signaling, subclin-
ical inflammation, hyperglycaemia, hyperinsulinaemia,
and increased IGF-1 signaling [15, 29]. Differential asso-
ciations of obesity and breast cancer risk by hormone
receptor status likely reflect a greater responsiveness of
ER+ / PR+ tumors to these mechanisms [4, 30]. How-
ever, it is largely unknown why obesity should predis-
pose to p53- and Bcl-2+ tumor subtypes in
postmenopausal women, as indicated by our data. The
expression of p53 in breast adipose stromal cells is
downregulated by obesity-induced prostaglandin E2
(PGE2), which results in a local upregulation of aroma-
tase activity and estrogen production [31], and estrogen
receptor has also been demonstrated to downregulate
p53 and cause tumor cell proliferation [31, 32]. Bcl-2
proteins, by contrast, have been proposed to exert
pro-apoptotic effects [12, 25, 33] and influence
p53-mediated cell-death [31, 34]. Thus, ER positivity,
Bcl-2 positivity and p53 negativity, which co-occurred in
a majority of breast cancer cases in the present analyses,
all appear to be part of a more general molecular con-
stellation that could be driven by obesity, even though
more experimental insight is needed to better under-
stand the interplay between obesity and these tumor
characteristics. In addition, larger epidemiological data-
sets are needed to stratify ER positive and ER negative
tumors by p53 or Bcl-2 status, which was not possible
due to sample size restrictions in the present study.
Our findings among postmenopausal non-users of HT
might suggest better prognosis in obese breast cancer
patients, as they may be more likely to have less aggres-
sive tumor subtypes than lean patients. Yet, prospective
analyses in cohorts of breast cancer patients have clearly
shown that breast cancer-specific survival is negatively
impacted by obesity irrespective of menopausal status or
hormone receptor status of the tumor [35, 36]. These
paradoxical observations may be explained by lower effi-
ciency of anticancer drugs, particularly aromatase inhibi-
tors, in obese patients and by better compliance to
treatment among normal weight patients [37]; still, fur-
ther studies are needed to resolve the paradox as to why
obesity may be related to an increased risk of less
aggressive breast tumors, while at the same time being
associated with worse prognosis irrespective of the
tumor subtype.
Several limitations apply to our study. First, by using
TMAs from preserved tumor material to assess tumor
subtypes, we ensured homogeneity of testing conditions.
However, when compared to full-slice IHC staining done
for diagnostic purposes, IHC performed on TMAs may
be more prone to misclassification of subtypes, especially
when the tumor tissue exhibits heterogeneous expres-
sion of the markers in question and visual estimation of
positive tumor cells is used. To minimize such misclassi-
fication, we used two tissue cores per tumor. Neverthe-
less, we cannot rule out that misclassification of tumor
subtypes diluted associations in our study to some
degree. Second, case numbers in our study may have
been too low to detect weaker associations in some sub-
groups, especially for the more rare and aggressive
cancer subtypes. Due to lower numbers of these tumors,
tests for statistical heterogeneity in the associations
between obesity and breast cancer risk across tumor
subtypes were limited. In this context, it is worth men-
tioning that in previous analyses of the full European
EPIC cohort, heterogeneity in BMI breast cancer risk
associations by ER/PR status was restricted to women
older than 65 years at diagnosis [4], and that our sample
size was not sufficient to further stratify analyses by age
groups. Thus, our main observation – associations of
obesity with less aggressive breast cancer subtypes – re-
quires replication in larger-scale studies and pooled ana-
lyses. This is also true with regard to further
stratification of analyses by histological types of breast
cancer and cancer stage (e.g. invasive vs. in situ or ductal
vs. lobular), for which case numbers in the present study
were not sufficient. Another limitation is that we did not
have data on family history of breast cancer for
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statistical adjustment. Finally, as many similar cohort
studies on BMI and breast cancer risk, we could not
address changes in weight over time, even though weight
changes in our population are moderate according to
self-reports [38].
Conclusion
In the present study, we evaluated associations between
obesity and breast cancer risk by tumor subtypes, as
defined by six immunohistochemical markers used in clin-
ical routine to guide treatment and determine prognosis.
Our data suggests that obesity is related to ER+, PR+,
HER2-, Ki67low, Bcl-2+ and p53- tumors, i.e. such with
lower aggressiveness, in postmenopausal women. Further
mechanistic studies are needed to determine which bio-
logical mechanisms underlie the detected associations,
and larger pooled analyses of prospective cohort data will
be required to further investigate relationships between
obesity and molecular breast tumor subtypes, and particu-
larly the less frequent subtypes, in more detail.
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